Detection of IGF-1 and phosphorylated site in PDGFr using proximity ligation assay by Magalam , Raghavendra
 
Faculty of Natural Resources and 
Agricultural Sciences 
 
Detection of IGF-1 and phosphorylated 
site in PDGFr using Proximity Ligation 
Assay 
 
 
 
Magalam Raghavendra 
 
Department of Microbiology 
Independent project • 30 hec • Second cycle, A1E  
Examensarbete/Sveriges lantbruksuniversitet, Institutionen för mikrobiologi,  
2014:9 • ISSN 1101-8151 
Uppsala 2014 
Detection of IGF-1 and phosphorylated site in PDGFr using 
Proximity Ligation Assay  
 
Magalam Raghavendra 
 
Supervisor:  Johanna Blomqvist, Swedish University of Agricultural Sciences, 
Department of Microbiology 
 
Assistant Supervisors: Masood Kamali-Moghaddam, Uppsala University, 
Department of Immunology, Genetics and Pathology 
 
Junhong Yan, Uppsala University,  
Department of Immunology, Genetics and Pathology 
 
Examiner:  Volkmar Passoth, Swedish University of Agricultural Sciences, 
Department of Microbiology 
 
Credits: 30 hec 
Level: Second cycle, A1E 
Course title: Independent project/degree project in Biology/Självständigt arbete i biologi -                
magisterarbete 
Course code: EX0732 
 
Place of publication: Uppsala 
Year of publication: 2014 
Title of series: Examensarbete/Sveriges lantbruksuniversitet, Institutionen för mikrobiologi 
No:  2014:9 
ISSN: 1101-8151 
Online publication: http://stud.epsilon.slu.se 
 
Keywords: PLA, IGF-1, PDGFβr, IgG, recombinant PDGFr, VEGF, solid phase, solution 
phase 
 
Sveriges lantbruksuniversitet 
Swedish University of Agricultural Sciences 
Faculty of Natural Resources and Agricultural Sciences 
Uppsala BioCenter 
Department of Microbiology 
  
 
ABSTRACT 
Proximity ligation assay (PLA) is a novel affinity based method used to detect proteins, 
protein-protein interactions and post-translational modifications. The detection of 
target molecules is achieved with the help of oligonucleotide labeled antibodies. The 
oligonucleotides attached on antibodies can be joined by ligation when the conjugates 
are brought in proximity by binding on the same target molecule (Gullberg et al., 2003). 
The ligated products can be used as templates in qPCR for quantification. PLA is 
performed in two approaches, 1) solid surface; where a solid  support is used to 
which a capture antibody is immobilized and target is incubated to capture 
antibody (Fredriksson et al., 2002). 2) The other approach is solution phase; where 
there is no solid support, hence no capture antibody is used nor any washing step, 
and target molecule is incubated directly with detection antibodies. In my project, I 
have utilized solution phase and solid phase PLA for detection of IGF-1 and detection of 
phosphorylation on platelet derived growth factor receptor (PDGFβr). 
This thesis project aimed to develop an assay for IGF detection and post-translational 
modification detection in vitro using proximity ligation. My experiment could not establish 
PLA as a standard assay for detecting IGF-1 and phosphorylated-PDGFβr on solid surface 
and in solution phase. However, the recombinant PDGFr molecule was successfully 
detected with solid phase PLA. In this thesis, advantages of PLA and possible reasons for 
unsuccessful detection of phosphorylated site on PDGFβr are discussed. 
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1. INTRODUCTION 
The GENCODE (version 7) project published that there are only 20,687 protein- encoding 
transcripts in a human being (Harrow et al., 2012, Venter et al., 2001). Although there 
are only few protein coding transcripts in a human, yet it is very complex to 
understand the protein biological functions. Hence, the current focus of the research 
in the field of protein interactions, post translational modifications and alternative 
splice variants, is to achieve a novel protein detection method, as this would help the 
researchers to understand the complexity of proteins. The detection of proteins is more 
complicated than the detection of the genes as protein synthesis involves alternative 
splicing and post translational modifications, thus there is demand to achieve new 
methods to detect proteins and novel biomarkers to diagnose diseases. (Gullberg et al., 
2004, Weibrecht et al., 2010). 
 
Detection of proteins is an important strategy to reveal the complex mechanisms of 
the living organism; of course there are few methods which are already available in the 
market today that help in detecting the target proteins, but there is always a constant 
hunt in achieving a small limit of detection and also detecting multiple targets in same 
sample at very low concentration. Thus it is very crucial to invent a novel tool which 
detects the target proteins at low concentration with high sensitivity and with high 
affinity bonding between the detection probe and target protein (Fredriksson et al., 
2002). 
1.1 Protein detection methods 
Mass spectrometry 
Mass spectrometry (MS) is one of the methods used in studying proteins and has been 
very useful from decades in detecting biomarkers such as those of cancer (Diamandis, 
2004, Zhang et al., 2004). Proteins can be ionized by two approaches, electron spray 
ionization (ESI) and matrix assisted laser desorption/ionization (MALDI) (Domon and 
Aebersold, 2006).  Firstly the intact proteins are ionized by one of the two methods 
mentioned above and then introduced to a mass analyzer. This approach is called 
“top bottom” strategy. The other approach is bottom up where the proteins are 
digested into small peptides by enzymes and introduced into mass spectrometry (MS) to 
characterize the protein in the sample (Domon and Aebersold, 2006). 
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MS basically measures the mass to charge ratio of gas phase ions. MS consists of an ion 
source which converts the analyte or sample into gas phase ions, the analyzer then 
separates the ions based on mass to charge ratio. The mass to charge ratio values of 
individual ions are recorded by a detector. In MS, the mass analyzer is the key for the 
complete technology and some of the examples of the analyzers are LTQ-orbitrap, time 
of flight (TOF) mass analyzer and Fourier transform ion cyclotron resonance (FTICR) mass 
analyzer (Han et al., 2008).  
Mass spectrometry apparatus 
The mass spectrometry process consists of four main stages; ionization, acceleration, 
deflection and detection. In the ionization step, the sample is bombarded by electrons 
coming from a high energy filament. During this step electrons from the sample are 
removed by electrons coming from heated filament. In the acceleration step ions are 
placed between a set of charged plates. These ions are repelled from one charged plate to 
another, finally there is slit in the plate to which ions are attracted at an accelerated rate. 
The acceleration of ions depends on charge on the plates. There is a highly powered 
magnet surrounding the apparatus. Deflection of sample ions is proportional to sample 
mass, lighter ions are deflected most. The ions which have correct charge reach to 
detector. In detection stage, ions are neutralized after hitting the detector and an 
amplifier would enhance the charge received into a detection signal, which ultimately 
would be converted to mass/charge ratio by computer software (Figure 1). 
http://chemicalinstrumentation.weebly.com/mass-spectrometry.html  
 
                         
Figure 1. Mass spectrometry: A) ionization; 1) Sample, 2) Electron beam, 3) slits, 4) Ion beam.B) Accelerator; 5) 
Accelerator plate C) Deflection; 6) Magnet 7) Deflection of ions D) Detector. Modified from 
(http://chemicalinstrumentation.weebly.com/mass-spectrometry.html) 
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ELISA 
Enzyme linked immuno-sorbent assay is a molecular tool which is extensively used in 
industries and laboratories as quality control and protein detection method (Green et al., 
1997, Savige et al., 2003). ELISA was first developed by the research group of Peter 
Pearlman and Eva Engvall in Stockholm and by the research group of Anton Schuurs and 
Bauke Van Weemen in the Netherlands in 1960. The basic principle involves antigens 
from a sample that are coated to the surface of a well on a microtiter plate, then an 
antibody specific to the antigen (detection antibody) is added to surface of the well to 
bind to the antigen and this antibody is linked to an enzyme, and finally an enzyme 
substrate is added and upon when enzyme linked antibody is attached to desired antigen 
there will be a colour change due to the substrate (Hnasko et al., 2011). The sensitivity of 
this assay can be increased by adding a secondary antibody that is linked to an enzyme 
(Hnasko et al., 2011). This antibody detects the primary antibody which is bound to 
antigen. In this case between each step, it involves a washing step so that unbound 
antibody- antigen complexes are discarded and when finally enzyme substrate is added 
we can visibly see a colour change in the experimental wells, the amount of colour 
changes is directly proportional to the amount of antigen and antibody bound complex 
(Voller et al., 1978). This amount of colour change can be analyzed under 
spectrophotometer and give us actual amount of antigen present in the sample. 
(http://www.abnova.com/support/resources/ELISA.asp).   
There are different types of ELISA; 1) Direct Elisa, 2) Indirect Elisa, 3) Sandwich Elisa, 4) 
Competitive Elisa. 
 
Figure 2. Elisa: 
1) direct Elisa: A) Substrate, B) Primary antibody conjugate, c) Antigen. 
2) Indirect Elisa: A) substrate, B) secondary antibody conjugate. 
3) Sandwich Elisa: A) Substrate, B) Capture antibody.  
4) Competitive Elisa: A) Inhibitor antigen, B) Substrate. 
1)  Direct Elisa; antigen is recognized by a fluorescent tagged detection antibody, 2) indirect ELISA;  antigen is 
recognized by a detection antibody and this antibody is further detected by fluorescent tagged antibody, 
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3) sandwich ELISA: the capture antibody detects the antigen and this antigen is further detected by detection 
antibody and finally this antibody is detected by a fluorescent tagged antibody and 4) target sample along 
with purified antigen competes to bind to secondary antibody immobilized on solid surface, then later 
primary antibody binds to this complex. (modified from http://www.abnova.com/support/resources/ELISA.asp) 
 
1.2 Proximity Ligation Assay 
The mystery of cellular function is yet to be unraveled to gain insights about proteins, 
post translational modifications. Although existing methods give us better 
understanding of proteins, researchers are constantly exploring new ways to 
implement the best method to detect protein and post translational modifications. In 
recent decades there have been major technological advancements such as making 
monoclonal antibodies, mass spectrometry, green fluorescent protein fusions, which 
enabled researchers to achieve insights into proteomics. 
Proximity ligation assay (PLA) is a method which uses monoclonal antibody and 
polyclonal antibodies technology to detect proteins. PLA also uses the same principle 
as ELISA, where antibodies are used as detector probes to detect target protein. But 
PLA stands apart from ELISA and other affinity based targeting methods with its dual 
recognition and high specificity (Gullberg et al., 2003). Proximity ligation assay also 
circumvents the cross-reactivity errors and non-specific adsorption. In this assay the 
antibodies are linked with an oligonucleotide using biotin-streptavidin chemistry. To 
achieve this interaction, the oligonucleotide is covalently linked to streptavidin through 
maleimide conjugation chemistry. Then this modified streptavidin oligonucleotide is 
linked to a biotinylated antibody. This antibody attached with oligonucleotide is 
directed towards the target in the sample (Söderberg et al., 2008, Gullberg et al., 2004). 
The main advantage of using this modified antibody is that streptavidin and biotin have 
high affinity to each other and that they are stable even at 95˚C (Green, 1990). When 
two or more detection probes bind to the same target molecule, the oligonucleotides 
present on these probes get ligated and form a single stranded DNA sequence when 
they are in close proximity. The ligated products are then amplified in qPCR. This 
nucleotide sequence will serve as template for primers and produce a single stranded 
circular nucleotide sequence and for every successful template formation a signal is 
generated and this signal is recorded by PCR machine software. 
Proximity ligation assay can be performed in two different approaches, solid phase PLA 
and solution phase PLA. In solid phase the main feature is that a primary antibody is 
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immobilized on solid surface, preferably magnetic beads (figure 3). Further when the 
immobilized primary antibody is incubated with the sample the antibody binds to the 
protein molecule. Finally the secondary antibodies detect the target molecule and 
generate a novel DNA strand which helps in providing detection signals in qPCR. In 
solution phase PLA primary and secondary antibodies are directly added to protein analyte 
solution without any immobilization of primary antibody on solid support (figure 3).  
Solid phase PLA method gives a broader dynamic range and low limit of detection (LOD) 
when compared to solution phase PLA or any other protein detection methods 
(Fredriksson et al., 2007). The another main advantage of this method is, during washing 
steps the unbound probes and non-specific molecules or any contaminants can be 
eliminated therefore reducing background noise. The solution phase is a very direct 
approach and less protein analyte solution is required and also this avoids any washing 
steps further reducing the sample consumption. Both approaches have proven to be 
successful in detecting multiple targets, while solid phase PLA provides low cross reactivity 
and detecting sample at very low concentration, solution phase PLA reduces sample 
amount and can detect multiple targets with single batch of polyclonal antibodies 
(Lundberg et al., 2011) 
 
Figure 3. Solid phase PLA. a) The capture antibody is immobilized on the solid surface, b) target antigen is 
captured by capture antibody, c) detection probes detect the target antigen, d) when detection probes are in 
close proximity the oligonucleotides present on the detection probes get hybridized and form a template 
sequence and e) primers amplify the template sequence and generate detection. Modified from (Darmanis 
et al., 2010).  
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Figure 4. Solution phase PLA: solution phase PLA does not require a micro-particle, thus no capture antibody. 
A) Target antigen is recognized by the detection probes, B) As detection probes are in close proximity the 
oligonucleotides present on the detection probes are hybridized with the help of ligase and C) the primers 
amplify the oligonucleotide sequence and amplify thus generating detection signal. Modified from Darmanis 
et al., 2010. 
 
1.3 Proximity Probes 
Proximity probes are the most important part of proximity ligation assay. There are 
different types of probes.  
Aptamers: Initially when PLA was designed, aptamers with 3’ and 5’ DNA extension were 
the first generation of proximity probes (Frederickson et al., 2002).. These aptamers are 
single stranded RNA or DNA oligonucleotides which are selected invitro and these 
aptamers are highly specific and shown to detect complex proteins in pico-molar to nano-
molar  concentrations (Bock et al., 1992), and are  specific to the target single epitope site 
and are used to detect high complex and pure proteins (Fredriksson et al., 2002), 
although these have high specificity, it is not recommended to use in sandwich. Since 
there are only very few suitable aptamers available, the most commonly used probes are 
mono clonal antibodies, polyclonal antibodies or immuno- globulins, which is 
combination of heavy chain and light chain (fb or fv) and these prove to be better option.  
Antibody probes 
In PLA most commonly used probes are monoclonal and polyclonal antibodies and these 
antibodies are attached with oligonucleotides. These probes are made by two different 
ways 1) covalent conjugate antibodies and 2) non-covalent conjugate antibodies 
(Lundblad, 2005). 
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Covalently Conjugated Antibodies 
The preparation of covalent conjugation of antibody with oligonucleotide is achieved with 
the help maleimide conjugate chemistry. In maleimide conjugation chemistry the primary 
amines on antibody are activated by a cross linker called SMCC (succinimidyl-4{n-
maleimidomethyl}cyclohexane-1-carboxylate). In conjugation, an antibody is treated with 
a small molecule like SMCC (succinimidyl-4{n-maleimiedomethyl}cyclohexane-1-
carboxylate), it exposes an activte ester to form amide bonds with amine groups on lysine 
chains and N terminus (Hermanson, 2008), (Kalia and Raines, 2010), This activated 
antibody is then attached to a thiol reduced oligonucleotide. The conjugation between 
oligonucleotide with antibody is confirmed with the help of SDS-page. Finally using HPLC 
(high performance liquid chromatography) the conjugate antibody can be purified. 
Non-covalent conjugation antibody 
In case of non-covalent conjugate antibody, the streptavidin modified oligonucleotide is 
attached to a biotinylated antibody. The Streptavidin molecule is attached to the 
oligonucleotide with the help of maleimide conjugate chemistry. These streptavidin 
modified oligonucleotides can be purchased from several companies, and these 
oligonucleotides can be directly attached to the biotinylated antibody without any 
purification steps. This streptavidin and biotin conjugate chemistry is used because of 
their high binding affinity to each other and they can with stand high pH and high 
temperature. 
During biotynylation of antibody the primary amines present on the antibody react with 
the biotin reagent. This biotin reagent consists of three parts, a biotin molecule, NHS sulfo 
group and a spacer arm. An amine bond is formed between biotin molecule and primary 
amine on antibody while NHS-sulfo group leaves and this enhances the solubility of the 
antibody in water. In this non-covalent conjugation reaction between biotin and antibody 
the spacer arm is very important as it enhances the binding between the biotin molecule 
on antibody and streptavidin molecule on oligonucleotide, and longer spacer arm also 
reduces the steric hindrance. 
Advantages and disadvantages of PLA probes  
While conducting experiments, the suitable probe is taken into consideration and pros 
and cons are weighed among each type of probes. The biotinylated probes are better 
suitable for conducting direct experiment as they require no purification step. Unlike 
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biotinylated probes, conjugated probes require excessive purification steps before 
conducting PLA experiment. Conjugated probes give better results in experiments where 
the target molecule is very small when compared to the biotinylated probes, because the 
biotin and streptavidin molecules add size to probes and hence may cause difficulties in 
detecting small molecules. Moreover, the biotin probes may cause hindrance and give 
high signals if the strep and biotin bond breaks. However, biotin probes are also very 
efficient in giving results because of the washing steps which will remove the unbound 
probes to target and because of biotin and streptavdin bonding. The washing step will 
not affect the already bound molecules and also these probes are very stable in solutions 
and also at high temperatures and high pH. But conjugated probes are very useful in 
multiplex PLA experiments, (when detecting different protein in parallel) as we can design 
different nucleotide sequences and make probes more efficient and reduce cross 
reactions (Fredriksson et al., 2007). 
1.4 IGF-1 
IGF-1, insulin-like growth factor is also known as somatomedin c. This is produced in liver 
and plays vital part in apoptosis, growth development or cellular differentiation.  Three 
main somatomedins have been characterized: somatomedin C (IGF-1), Somatomedin A 
(IGF-2) and somatomedin B (Rosenfeld, 2003). IGF-1 is studied in this thesis as this protein 
is involved in cancer related diseases (Baserga et al., 2003), and muscular diseases 
(Musaro and Rosenthal, 2002). As the PLA has shown to detect molecules at very low 
concentrations (Blokzijl et al.,) it could be a very important assay if a standard assay is 
established to detect the IGF-1 molecule at low concentrations in order to diagnose early 
IGF-1 related diseases. 
IGF-1 is a cytokine that is activated when attached to its receptors, IGF-1R, whose effects 
are altered by its binding proteins, and there are six different insulin like growth factor 
binding proteins (IGFBP) (Forbes et al., 2012). 
 
Insulin like growth factor-1 is a single chain 70 amino acid based protein consisting of a 
hydrophobic core having 3 helices and 3 disulphide bonds which help in structure 
conformation. (Figure 5) (Vajdos et al., 2001). IGF-1 has a total molecular mass of only 7.6 
kD. IGF-1 also shows significant   sequence identity to insulin (Rinderknecht et al., 1978). 
Although IGF-1 has homology to insulin structure, it still has very specific interaction with 
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its receptor and insulin does not show any interaction with IGF-1 receptor (Zhu et al,, 
1997).  
 
Figure 5. IGF-1 is a 70 amino acid protein which has a hydrophobic core having 3 helices, 3 disulhide bonds 
which stabilize structural conformation.  The C-terminus is largely responsible for IGF-1R specificity and 
this region is not homologous to insulin.  
Modified from (Vajdosetal.,2001) and (http://www.rcsb.org/pdb/explore/explore.do?structureId=1IMX) 
1.5 PDGF 
Platelet derived growth factor is a protein which regulates cell growth and division of cells, 
helping in formation of new blood vessels. In responses to injury like wound repair and in 
tissues that maintain themselves by continual cell turnover such as body cavities and in 
the hematopoietic system, PDGF helps in cell proliferation and in cell development 
(Andrae et al., 2008). The basis of cell proliferation whether it is normal or abnormal 
proliferation, lies within a group of hormones or growth factors (Ross et al., 1974).  
The PDGF is a potent mitogen for mesenchymal cells which consists of PDGF-1 and PDGF-11 
polypeptide chains and these are linked by disulphide bonds and they have a molecular 
weight of about 31-33 kDa. (Andrae et al., 2008, Sariban and Kufe, 1988). There are three 
members of the PDGF family – PDGFAA, PDGFAB and PDGFBB (Hannink and Donoghue, 
1989). PDGFs are expressed in the heart, the brain, skeletal muscle and placenta. They 
are required for the recruitment of pericytes and vascular smooth muscle cells and 
contribute to neural regeneration. PDGFs modulate intracellular signalling through the 
MAPK, PI3-K and PKC-gamma pathways via PDGF receptor (Heldin et al., 1992).   
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PDGF and interaction with PDGF isoforms 
The three different PDGF isoforms PDGFAA, PDGFAB, PDGFBB interact with two different 
PDGF receptors, alpha (α) and beta (β) (Claesson-Welsh, 1996). The alpha, (α ) type 
receptor binds to PDGF-AA, PDGF-BB and PDGF-AB isoforms, whereas beta (β) type 
binds to PDGF-BB and PDGF-AB. In PDGF there are eight cysteine residues which are 
conserved and among these, six form intra chain disulphide bonds, resulting in a knot like 
structure and rest of the two form intrachain bonds with other subunits. (Heldin et 
al.,1998, Jaumann et al., 1991). There are three different loops present in the knot like 
protein structure which is stabilized by β-sheets pointing in different directions, and 
these just not only stabilize but also have an active role in receptor binding (Heldin et al., 
1998, Andersson et al., 1995). Although there is abundant knowledge about PDGF, but 
unfortunately there is little advancement in detecting the protein or phosphorylated 
PDGF. Hence in this experiment, it is emphasized on detecting the phosphorylated 
PDGFβ-r on solid phase PLA to achieve a leap in molecular techniques. 
Receptor 
The bivalency of PDGF facilitates dimerization (Heldin et al., 1998) and the PDGF 
receptors are activated due to the dimerization which triggers kinase activation and 
maximal kinase activity is achieved as a result of tyrosine phosphorylation on PDGF 
receptor. Different types of PDGF receptors of homo or heterodimers are formed 
depending on the PDGF isoform (Ostman and Heldin, 2007). Actual sites for 
phosphorylation on α-receptor are not known, but the PDGF-β receptor is a tyrosine 
kinase protein which becomes dimerized and auto-phosphorylated by binding of an 
isoform like PDGF-BB which leads to signaling pathways (Oefner et al., 1992, Jarvius et al., 
2007). 
1.6 qPCR 
The PLA method detects proteins with the help of antibodies similar to ELISA or any other 
assay which uses immuno binders, but unlike other assays here the detection probes are 
modified into single stranded DNA template upon detecting the target protein, which can 
be later amplified with the help POLYMERASE CHAIN REACTION (PCR). In qPCR the single 
stranded DNA template is multiplied for every cycle just like normal PCR.  In qPCR the 
amplified molecules are measured through two strategies one is through fluorescent dyes 
such as sybr green and other is through TAQ-MAN probes. In this method TAQMAN probe 
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is utilised, which uses a fluorophore and a quencher, and when the primer is extended and 
forms a new strand, the fluorophore is released from the proximity of quencher molecule 
which emits fluorescence which is measured by a detector. In qPCR, X-axis is the number 
of amplification cycles and Y axis is the fluorescence of each cycle. As the curve of the 
amplification plot reaches exponential phase a threshold for fluorescence is set in 
background. Threshold cycle (Ct value) is the number of cycles at the intersection between 
amplification curve and a threshold line of fluorescence. The Ct value is inversely 
proportional to the initial concentration of the target which means the Ct value is higher 
when the initial template concentration is low. In PLA the concentration of the unknown 
target is measured from lowest to the highest, which is in amplification plot the higher 
concentration of target in sample the lower the Ct . In PLA the unknown target 
sample is serially diluted with target compatible matrix and a standard curve is drawn with 
Ct value of each sample against the concentration each sample. Along with standard curve 
a LOD (limit of detection) is measured which is the lowest amount of concentration of 
target detected with little amount of error. 
2. AIM 
Aim of the project was to develop the already existing technology, Proximity Ligation Assay 
(PLA) and achieve the detection of biomarker IGF-1 and phosphorylated PDGF receptor 
molecule in solid phase PLA and solution phase PLA using biotinylated proximity probes 
and conjugate probes. 
3. MATERIALS AND METHODS 
3.1 Buffers, proteins and oligonucleotides 
1x PBS buffer had a pH 7.4, 137 mM NaCl, 2.7 mM KCL, 10 mM sodium phosphate dibasic, 
2mM potassium phosphate monobasic. PLA buffer consisted 1 mM D-biotin, 0.1% purified 
BSA, 0.5% tween-20, 10 mM goat IgG (Invitrogen), 0.1 μg/μl salmon sperm DNA 
(Invitrogen), 5mM ETDA in 1x PBS. All the salts were ordered from Sigma Aldrich. 
Washing buffer, PBS-Tween consists of 0.05% tween-20 in 1xPBS and the storage buffer 
were 1x PBS in 0.1% BSA. 
Antibodies*:                                                                                                      
Human PDGF R beta affinity purified antibody, goat IgG                     
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Phospho-PDGF R beta (Y751) affinity purified Ab, Rabbit IgG                   
Human IGF-1 Mono-clonal Ab (Clone 33255), Mouse IgG                           
Human/ Mouse IGF-1 polyclonal antibody                                                     
Biotin anti Human IGF-1 recombinant    
*all antibodies were purchased from R&D systems.                                                                 
Oligonucleotides 
Taq-man probe   5'-TET TGTACGTGAGTGGGCATGTAGCAAGAGG-3'-TAMRA                                                                                      
(                                      (TET, tetra-chlorfluorescein; TAMRA, carboxytetramethylrhodamine) 
 
 SLC 1         Streptavidin-5'-CGCATCGCCCTTGGACTACGACTGACGAACCGCTTTGC 
CTGACTGATCGCTAAATCGTG-3' 
 
SLC2  5'-GTGTCTAAAGTCCGTTACCTTGATTCCCCTAACCCTCTTGAAA AATTCGGCATCGGTGA-
3'-Streptavidin  
 
Bio FWD     5'-CATCGCCCTTGGACTACGA-3' 
 
Bio REV    5'-GGGAATCAAGGTAACGGACTTTAG-3'  
 
Bio-Splint 5'-TACTTAGACACGACACGATTTAGTTT-3' 
3.2 Antibody Immobilization 
In solid phase method, dyna magnetic streptavidin beads were used as solid surface on 
which the antibody was immobilized as capture molecule.  To immobilize the antibodies 
on beads, 100 μl (10 mg/ml) of dynabeads was taken and storage solution from the beads 
was removed with the help of a magnet and a pipette and then the beads were washed 
twice with 500 μl of washing buffer. 200 µl of already prepared 50 mM antibody was 
added to the magnetic beads and then incubated for one hour, after one hour of incubation 
the antibody would be attached to the solid surface. The remaining liquid was removed 
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from the beads with the help of magnetic stand and a pipette. Now finally the beads were 
washed again with washing buffer and PBS was added as storage liquid into beads and 
then the solution was stored at 4 ºc. 
3.3 Preparation of proximity probes 
Commercially bought biotinylated antibody was added in two tubes and then incubated 
for 45 minutes with SLC1 and SLC2 oligonucleotides separately with the final concentration 
of 50nM and incubated them. During the incubation the streptavidin oligonucleotides and 
biotin antibody are attached. This biotin antibody and oligonucleotide complex was 
added with PBS/BSA separately so that these antibodies do not cross react with each 
other, and finally these probes were  diluted to either 250 pM or 500 pM with the PLA 
buffer for solid phase PLA and 60 pM for solution phase PLA. 
3.4 Solid Phase 
Serial dilutions were prepared, preferably six serial dilutions from highest to lowest from 1 
nM to 0.01 pM and a negative control without target protein sample was made. The 
immobilized antibodies on beads were diluted 5 times with PLA buffer. On a 96 well PCR 
plate, 45 μl of recombinant target protein was added to 5 μl of beads except for negative 
control, where only PLA buffer was added instead of protein and then the reaction mixture 
was incubated at room temperature on a rotator for 90 minutes. After the incubation 
process was finished the reaction wells were washed. The PCR plate was placed on a 
magnetic stand and washed twice with PBStween solution to remove unbound 
molecules. Then 50 μl of 500 pM concentrated probe (detection antibodies) was added 
to each well including to the negative control and the PCR plate was incubated at room 
temperature for 90 minutes. Then the washing step was carried again to remove unbound 
probe molecules. 
Finally 50 μl of PCR mix was added in to each well and placed in a qPCR thermo cycler.  
The PCR mix consisted of 5 μl of 10x PCR buffer, 2.5 μl MgCl2 50mM, 1.1 μl Taqman-
probe 10 μM, 0.5μl Biofwd 10 μM, 0.5 μl Biorev10 μM, 0.5 μl Bio splint 10 μM, 0.04 ATP 
10 mM, 0.4 μl DNTP’s 25 mM with dUTP, 0.3 μl Taq-pol 5 units/μl, 0.02μl T4 DNA Ligase 30 
U/μl, 0.10 μl UNG 1units/μl and water was added to make the mixture to 50 μl for each 
reaction.  The qPCR was programmed to following conditions: 95 ºC for 2 min, followed by 
40 cycles of 15sec 95 ºC and 1 min 60 ºC.  
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3.5 Solution Phase 
Unlike solid phase in solution phase only 60 pM conc. probes were used. Here a dilution 
series was prepared from 1 nM to 0.01 pM, and a negative control. In this method the 
antibodies were not immobilized on solid surface hence there was no capture antibody 
like in solid phase, therefore this method was not as accurate as solid phase. In this 
method the antigen or target sample was incubated directly with 60 pM probe at 1:1 
ratio for 90 minutes. 
After incubation, 2 μl of antigen + probe sample was added to 48 μl of PCR mix (similar 
to solid phase) in a new well and then the PCR plate was placed in a qPCR thermo cycler. 
The qPCR was programmed  to following conditions: 95 ºC for 2 min, followed by 40 
cycles of 15sec 95 ºC and 1 min 60 ºC. 
3.6 Data Analysis 
The qPCR results were analysed by Mx-pro software and the achieved results were 
transferred to an excel sheet to plot a graph. In the graph the Ct values were determined 
for each well and these values were taken down and a mean and standard error were 
calculated and with these numbers a graph was drawn with x-axis as concentration 
values from lowest to highest and y-axis ct values. R2 was calculated from the slope of 
the graph curve and a limit of detection (LOD). Limit of detection, defined as the 
concentration at rolling circle amplification (RCA) counts 2×SD over background was also 
calculated. Dynamic range is the total log difference between highest sample 
concentrations to the negative control. 
4. RESULTS 
4.1 Detection of IGF-1 on solid phase PLA 
The main objective of this experiment was to detect IGF-1 protein in animal tissue sample 
and human cerebral spinal fluid (CSF) in solid phase PLA and solution phase. Before trying 
to detect IGF-1 in a patient CSF sample, the PLA experiment was performed to detect 
recombinant IGF-1in buffer with the help of biotin antibodies. In this solid phase assay 
the antibody against IGF-1 was immobilized on magnetic beads and detection antibodies 
were incubated with capture antibody and target molecule complex. The Ct values were 
obtained using qPCR for 1 nM to 0.001 pM serial dilutions of recombinant IGF1 sample 
and positive control vascular endothelial growth factor recombinant protein (VEGF). VEGF 
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was used as a positive control in order to validate the results as detection of VEGF using 
this solid phase assay was already reported (Schallmeiner et al., 2007). 
A graph was plotted using Ct values versus sample dilution concentrations (figure 6).  
The IGF-1 protein was not detected in low concentrations (0.001 pM to 1 pM), also the 
difference in the Ct value between the 0.001pM and 1nM was not significant enough to 
conclude the detection experiment as successful. In contrast, the positive control, which 
was conducted under same the conditions as IGF-1 got good signals and showed 
difference of eleven Ct values. This experiment has proved me that the detection of IGF-1 
in patient CSF sample could not be possible, because the antibodies could not detect the 
recombinant IGF-1 protein. Limit of detection (LOD) for IGF-1 (with r 2=.812) was ~10 pM 
and with only 5 ct values difference in dynamic range. LOD for VEGF (r 2 =0.929) was less 
than 1pM and respectively and with dynamic range of ~ 9 Ct difference.  
 
 Figure 6. Detection of IGF-1 biomarker using PLA on solid phase in PLA buffer using biotinylated IgG 
antibodies. VEGF served as positive control. The X- axis shows the concentration of the IGF-1 dilution series 
from 1nM to 0.001pM. At 0.001pM there is no antigen in it, but only detection probes. On Y-axis, the 
average of Ct values of the PCR results are plotted, and along the slope there are error bars which give the 
standard deviation from same sample replicate measurements of several independent dilutions. 
4.2 Detection of IGF-1 in solution phase 
The main difference between solution phase and solid phase is that the detection of 
molecules is direct in solution phase and does not require any additional washing step 
and can be done very easily. In solution phase the target molecule is directly incubated 
with the conjugate probes. In this experiment, IGF-1 molecule was incubated with 60 
pM conc. detection probes. Later, the samples along with probes were amplified in 
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qPCR. The results obtained with the solution phase shown in figure 7 indicated that the 
solution phase proved to be less effective than solid phase experiment. Figure 7 shows 
that all IGF-1 serial dilutions had the same Ct values indicating that detection of 
recombinant IGF-1 was unsuccessful. In contrast, the positive control (VEGF) (r 2 =0.8847) 
gave good signals achieving low limit of detection of 0.01 pM and a dynamic range of ~9 
ct values difference.  
      
Figure 7. Detection of IGF-1 biomarker using PLA on solution phase in PLA buffer with smcc conjugated IgG 
antibodies. VEGF served as positive control. The X- axis shows the concentration of the IGF-1 dilution series 
from 1 nM to 0.001 pM. At 0.001pM there was no antigen present, but only detection probes. On Y-axis, 
the average of Ct values of the PCR results are plotted, and along the slope there are error bars which give 
the standard deviation from same sample replicate measurements of several independent dilutions. 
4.3 Detection of phosphorylated PDGFr in cell lysates on solid phase 
The cell lysate sample containing activated PDGFβr was incubated with detection antibody 
that was immobilized on solid particles (dyna magnetic beads). Proximity probes or 
detection probes to detect the PDGFr were attached with oligonucleotides using 
maleimide conjugation chemistry. Two different batches of phosphor detecting antibodies 
were made, each having different oligonucleotides attached to them. One of these two 
phospho-site detecting antibodies served as ARM1 and other antibody served as ARM2.   
ARM 2 phospho detection antibody which detects the phosphorylated tyrosine 750 site on 
PDGFβr was used (Figure 8). This antibody serves as secondary detection antibody which 
detects phosphorylated site and the other polyclonal antibody as primary antibody which 
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detects PDGFr protein. Similarly ARM 1 of phospho detection antibody was used to detect 
the phosphorylated site on PDGFβr and anti PDGFr antibody served as ARM2 (Figure 9). 
In this solid phase experiment to detect phosphorylated PDGFr, cultured cells were 
treated with PDGF-BB cytokine to phosphorylate PDGFr.  
Recombinant PDGFr was used as a positive control and lysis buffer was used as negative 
control and stimulated (+) cell lysate was the target. Figure 8 and 9 show that there was a 
linear increase in detection values of recombinant PDGFr and there was a 12 Ct value 
difference (dynamic range) from 0.001 pM to 1nM with LOD of (r2 =0.966) at 0.01pM  
However, for stimulated (+) cells, the Ct values obtained for all dilutions did not differ from 
each other. Similarly, it was also observed in non-stimulated cells that the Ct values were 
in same range from 0.0001 pM to 1 nM. Both the experiments have resulted in 
unsuccessful detection of phosphorylated PDGFβr.  
 
 
 
Figure 8. Detection of phosphor-PDGFr using PLA on solid phase in PLA buffer with smcc conjugated IgG 
antibodies. Recombinant-PDGFβr served as positive control. The X- axis shows the concentration of the 
sample dilution series from 1 nM to 0.001 pM. At 0.001 pM there was no antigen in it, but only detection 
probes. On Y-axis, averages of Ct values of the PCR results are plotted, and along the slope there are error 
bars which give the standard deviation from the same sample replicate measurements of several 
independent dilutions. 
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Figure 9. Detection of phospho-PDGFr using PLA on solution phase in PLA buffer with smcc conjugated IgG 
antibodies. Recombinant-PDGFβr served as positive control. The X- axis shows the concentration of the 
sample dilution series from 1nM to 0.001pM. At 0.001pM there was no antigen in it, but only detection 
probes. On Y-axis, averages of Ct values of the PCR results are plotted, and along the plot there are error 
bars which give the standard deviation from same sample replicate measurements of several independent 
dilutions. 
 
4.4 Comparison of detection signals of phosphorylated PDGFβr in 
diluted samples 
To study the phosphorylation of PDGFβr, the tyrosine 751-Phophosphrylated site 
detection antibody was purchased from R&D systems. This antibody was made into two 
different batches attached with different oligonucleotides. They are named as ARM1 
(Y751 13042) and ARM2 (Y751 130582). For a successful detection of PDGFβr protein, I 
have used a Human PDGF R beta Affinity Purified Polyclonal Ab, Goat IgG as a primary 
antibody to detect the PDGFr protein, followed by Phospho-PDGF R beta (Y751) Affinity 
Purified Polyclonal Ab, Rabbit IgG as a secondary antibody to detect the tyrosine 
phosphorylated site on the PDGFβr protein. In experiments mentioned above (Figure 
8,9) it was observed that the antibodies were unsuccessful in detecting the 
phosphorylated PDGFβr site, hence in this experiment I wanted to investigate whether 
the Phospho-PDGF R beta (Y751) ARM1 and ARM2 antibodies were contaminated or  
there was any cross reaction activity between the antibodies.  
In an ideal PLA experiment, Ct value for a sample without target (protein) is usually high 
and Ct value for a sample with target protein is low. In other words, the higher the 
sample concentration, the lower the Ct value. However, in this experiment the lysis 
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buffer Ct value was unusual. At 100x dilution lysis buffer Ct value was lower than 10x 
dilution (Figures 10, 11). As 100x was more diluted than 10x, the Ct value of higher 
diluted sample should be more than the lesser diluted sample. 
           
Figure 10. Detection of phosphor-PDGFr using solid phase in PLA buffer with smcc conjugated anti-
PDGFβr IgG antibodies from R&D systems control. The X- axis is the dilution in times of the sample. On Y-
axis, the average of Ct values of the PCR results are plotted. (+) represents; cell lysate sample with 
phosphorylated PDGFβr, (-) represents non phosphorylated PDGFβr cell lysate. Lysis is the lysis buffer.  
 
 
            
 
Figure 11. Detection of phosphor-PDGFr using solid phase in PLA buffer with smcc conjugated anti-
PDGFβr IgG antibodies from R&D systems control. The X- axis shows the dilution in times of the sample. 
On Y-axis, the average of Ct values of the PCR results are plotted. (+) represents; cell lysate sample with 
phosphorylated PDGFβr, (-) represents non phosphorylated PDGFβr cell lysate. Lysis is the lysis buffer . 
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5. DISCUSSION 
Proximity ligation assay (PLA) is an evolving method to study the interactions between 
biomolecules at protein level. Understanding the post transcriptional modifications of 
proteins would enable us to understand human diseases (Wilkins et al., 1999, Mann et 
al., 2003). The goal of proteomics is to identify individual proteins at low concentrations 
in a tissue or in fluids, which requires high accuracy and sensitivity to investigate 
biomarkers. There are already existing protein detection methods such as microarray, 
chip, or mass spectrometry, by which   many biomarkers have been identified, but PLA 
allowed looking into the relation of proteins to human diseases.  
In this thesis, I have employed solid phase and solution phase approaches to study IGF1 
and phosphorylated PDGFβR, to establish as a biomarker using PLA for cancer related 
diseases and to understand cell-cell signaling respectively. 
Simon Fredriksson et, al have reported plasma biomarkers in pancreatic cancer and 
ovarian cancer, a study which included IGF-2 (Fredriksson et al., 2007). IGF-1   structurally 
homologous to IGF-2, is an anabolic hormone produced in liver and taking part in 
protein catabolism and glucose utilization. But recently it was also reported as a possible 
biomarker for cancer (Borofsky et al., 2002, Rosenfeld, 2003). Recently, IGF-1 has been 
reported as a biomarker for cystic fibrosis (CF), (Gifford et al., 2013) with ELISA. However, 
the ELISA used in this study could only detect the target protein at more than 1ng/ml 
which is higher limit of detection than PLA. But the PLA could detect the protein at less 
than 1pM concentration and also it uses very low amount of detecting antibodies, 
therefore reducing the cross reaction between antibodies. Thus it would be a 
remarkable assay to study the target protein and its association to cancer or any other 
disease. PLA not only  detects low concentrated protein, but  also other proteins in same 
sample at same time called as multiplexing, thus enabling researchers to study other 
cytokines related to target protein (Chang et al., 2009, Tavoosidana et al., 2011). 
In my experiments, I have tried to detect recombinant IGF-1 protein and later to establish 
an assay to detect IGF-1 in serum samples. In Figure 6, it was observed that, PLA could not 
detect the target protein (IGF-1), but it was successful in detecting recombinant VEGF, in 
the positive control. But still at higher sample concentration it was observed that anti -IGF-1 
antibodies were able to detect IGF-1. The possible explanation for not detecting protein 
may be due to the fact that the IGF-1 molecular weight is 7.6 kD, which would make it 
difficult for detecting antibodies to detect the appropriate epitope site of the target 
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protein molecule, as the detecting antibodies have molecular weights of 150 kD excluding 
the molecular mass of streptavidin and biotin. To overcome this problem I have employed 
solution phase PLA to reduce the amount of capture antibodies, so that this technique 
could expose several epitopes for detection probes to recognize the IGF-1. But this effort 
did not give positive results (Figure 7), where positive control (VEGF) was detected but IGF-
1 protein data showed only detection antibodies signals.  
Detection of phospho-PDGFβr 
Another crucial effort made with PLA was to establish a standard assay which could detect 
the specific phophorylation site on a receptor, so that it would enable researchers to study 
the molecular mechanism, course of events that would take place in a cell after a 
successful activation of specific phosphorylated site on a receptor.  
In my experiments, I have used solid phase PLA to detect the PDGFβ receptor, which is 
found to be essential for cell growth and chemotaxis, (Heldin, 1992). PDGFβr detection with 
PLA in situ with dual recognition was already reported (Jarvius et al., 2007). According to 
their study a primary antibody detects PDGFβr site and a secondary antibody detects the 
phosphorylated site. In my thesis I have employed the same technique to detect the 
phophorylated PDGFβr, but on solid surface in HEK293 cell lysate samples. 
In this thesis, I have tried to detect the PDGFβr with dual recognition, where one primary 
antibody detects the PDGFβr and the other primary antibody detects the phosphorylation site 
on PDGFβr. Before conducting the experiment to detect the receptor, the HEK293 cells were 
pre-treated with PDGF-BB isoform to activate the PDGFβr and to auto phosphorylate at 
tyrosine 750. The experimental results showed that the detection of phosphorylated PDGFβr 
was unsuccessful (Figure 9). This could be due to the differences in levels of ligand-induced 
receptor phophorylation (Jarvius et al., 2007). Another possible explanation for unsuccessful 
detection could be due to cell lysis buffer. In cell lysis buffer to inhibit the phosphatase 
enzyme action, phosphatase inhibitor was added. The unsuccessful detection of the 
phosphorylated receptor may be because of inadequate amount of phophatase inhibitor in 
lysis buffer.  
Another reason for unsuccessful detection of PDGFβr may because of anti-phospho PDGFβr 
antibodies. In my experiment I have used polyclonal antibodies for detecting positive control 
(recombinant PDGF receptor) and the same antibody along with anti-phospho PDGFβr 
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antibody was also used to detect phosphorylated PDGFr. The antibody which was used in 
detection of recombinant PDGFr was effective in recognizing recombinant-PDGFr (figure 9). 
But the same antibody along with anti-phophorylated PDGFβr antibody was proved to be 
unsuccessful in detecting phosphor-PDGFβr, suggesting that Phospho PDGFβr antibody could 
be the reason for unsuccessful detection. 
In order to assess the possible reason for antibodies not detecting receptor, I have compared 
(+) ARM1 and (-) ARM2 antibodies of anti- phospho-PDGFβr and tried to find which ARM was 
better in detecting phospho-PDGFβr. However, both ARM’s have showed linear Ct values for 
whereas lysis buffer showed  high Ct values with high background (figure 10, 11), suggesting 
again lysis buffer could be one of possible reasons for showing high background. However, it is 
still unclear why the detection of phosphorylated receptor on solid phase PLA in cell lysate 
samples  was unsuccessful, even though PLA showed remarkable ability to recognize multiple 
phosphorylated receptors in situ (Chen et al., 2013, Jarvius et al., 2007). 
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